These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19808873)

  • 1. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.
    Briasoulis E; Pappas P; Puozzo C; Tolis C; Fountzilas G; Dafni U; Marselos M; Pavlidis N
    Clin Cancer Res; 2009 Oct; 15(20):6454-61. PubMed ID: 19808873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer.
    Rajdev L; Negassa A; Dai Q; Goldberg G; Miller K; Sparano JA
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1119-24. PubMed ID: 21373895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial.
    Gridelli C; Manegold C; Mali P; Reck M; Portalone L; Castelnau O; Stahel R; Betticher D; Pless M; Pons JT; Aubert D; Burillon JP; Parlier Y; De Marinis F
    Eur J Cancer; 2004 Nov; 40(16):2424-31. PubMed ID: 15519515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
    Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
    Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
    Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
    Hirsh V; Desjardins P; Needles BM; Rigas JR; Jahanzeb M; Nguyen L; Zembryki D; Leopold LH
    Am J Clin Oncol; 2007 Jun; 30(3):245-51. PubMed ID: 17551300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
    J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
    Addeo R; Sgambato A; Cennamo G; Montella L; Faiola V; Abbruzzese A; Capasso E; Leo L; Botti G; Caraglia M; Del Prete S
    Clin Breast Cancer; 2010 Aug; 10(4):301-6. PubMed ID: 20705563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
    Mundt AJ; Rotmensch J; Waggoner SE; Yamada D; Langhauser C; Fleming GF
    Gynecol Oncol; 2001 Aug; 82(2):333-7. PubMed ID: 11531289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.
    Freyer G; Delozier T; Lichinister M; Gedouin D; Bougnoux P; His P; Imadalou K; Trillet-Lenoir V
    J Clin Oncol; 2003 Jan; 21(1):35-40. PubMed ID: 12506167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours.
    Bourgeois H; Vermorken J; Dark G; Jones A; Fumoleau P; Stupp R; Tourani J; Brain E; Nguyen L; Lefresne F; Puozzo C
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):407-13. PubMed ID: 17541591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
    Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
    Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
    Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
    Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.